Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Steinbach

Showing results (251-260 of 369) with videos related to

Pageof 37
Sort By:
Oncoimmunology|October 17, 2022
AAV-mediated gene transfer of a checkpoint inhibitor in combination with HER2-targeted CAR-NK cells as experimental therapy for glioblastomaM I Strecker, K Wlotzka, F Strassheimer, et al.
Neuropathology and Applied Neurobiology|October 20, 2020
Linking epigenetic signature and metabolic phenotype in IDH mutant and IDH wildtype diffuse gliomaYannick Braun, Katharina Filipski, Simon Bernatz, et al.
European Journal of Cancer (Oxford, England : 1990)|January 25, 2015
A randomised, open label phase III trial with nimotuzumab, an anti-epidermal growth factor receptor monoclonal antibody in the treatment of newly diagnosed adult glioblastomaManfred Westphal, Oliver Heese, Joachim P Steinbach, et al.
Clinical and Translational Medicine|November 18, 2024
An AMP-activated protein kinase-PGC-1α axis mediates metabolic plasticity in glioblastomaBenedikt Sauer, Jan Kueckelhaus, Nadja I Lorenz, et al.
Brain Pathology (Zurich, Switzerland)|December 10, 2016
CASP9 germline mutation in a family with multiple brain tumorsMichael W Ronellenfitsch, Ji-Eun Oh, Kaishi Satomi, et al.
Neuro-Oncology Advances|August 26, 2024
Survival probability of epigenetically defined IDH-wild-type glioblastoma without necrosis or vascular proliferationPatrick N Harter, Katharina J Weber, Franz L Ricklefs, et al.
Cell Death Discovery|March 28, 2026
Targeting glioblastoma mitochondrial metabolism with S-Gboxin induces cytotoxicity under conditions of the tumor microenvironmentJan-Béla Weinem, Hans Urban, Benedikt Sauer, et al.
International Journal of Molecular Medicine|April 24, 2020
AMPK activation protects astrocytes from hypoxia‑induced cell deathLeli Barialai, Maja I Strecker, Anna-Luisa Luger, et al.
The Lancet. Oncology|May 15, 2012
Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trialWolfgang Wick, Michael Platten, Christoph Meisner, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 7, 2009
Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma NetworkMichael Weller, Jörg Felsberg, Christian Hartmann, et al.
Pageof 37

Showing results (251-260 of 369) with videos related to

Sort By:
Pageof 37
Oncoimmunology|October 17, 2022
AAV-mediated gene transfer of a checkpoint inhibitor in combination with HER2-targeted CAR-NK cells as experimental therapy for glioblastomaM I Strecker, K Wlotzka, F Strassheimer, et al.
Neuropathology and Applied Neurobiology|October 20, 2020
Linking epigenetic signature and metabolic phenotype in IDH mutant and IDH wildtype diffuse gliomaYannick Braun, Katharina Filipski, Simon Bernatz, et al.
European Journal of Cancer (Oxford, England : 1990)|January 25, 2015
A randomised, open label phase III trial with nimotuzumab, an anti-epidermal growth factor receptor monoclonal antibody in the treatment of newly diagnosed adult glioblastomaManfred Westphal, Oliver Heese, Joachim P Steinbach, et al.
Clinical and Translational Medicine|November 18, 2024
An AMP-activated protein kinase-PGC-1α axis mediates metabolic plasticity in glioblastomaBenedikt Sauer, Jan Kueckelhaus, Nadja I Lorenz, et al.
Brain Pathology (Zurich, Switzerland)|December 10, 2016
CASP9 germline mutation in a family with multiple brain tumorsMichael W Ronellenfitsch, Ji-Eun Oh, Kaishi Satomi, et al.
Neuro-Oncology Advances|August 26, 2024
Survival probability of epigenetically defined IDH-wild-type glioblastoma without necrosis or vascular proliferationPatrick N Harter, Katharina J Weber, Franz L Ricklefs, et al.
Cell Death Discovery|March 28, 2026
Targeting glioblastoma mitochondrial metabolism with S-Gboxin induces cytotoxicity under conditions of the tumor microenvironmentJan-Béla Weinem, Hans Urban, Benedikt Sauer, et al.
International Journal of Molecular Medicine|April 24, 2020
AMPK activation protects astrocytes from hypoxia‑induced cell deathLeli Barialai, Maja I Strecker, Anna-Luisa Luger, et al.
The Lancet. Oncology|May 15, 2012
Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trialWolfgang Wick, Michael Platten, Christoph Meisner, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 7, 2009
Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma NetworkMichael Weller, Jörg Felsberg, Christian Hartmann, et al.
Pageof 37